1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Value Of AbbVie’s Cerevel Buy Uncertain After Schizophrenia Failure

Phase II Misses Could Benefit BMS’s Cobenfy

 
• By Joseph Haas

With two misses for emraclidine, AbbVie will hope to extract some value from the Cerevel acquisition from the Parkinson’s drug tavapadon, while BMS may get a big lead in the schizophrenia space.

AbbVie exterior
AbbVie's emraclidine failed two Phase II studies in schizophrenia • Source: Alamy

AbbVie and Bristol Myers Squibb grabbed headlines last December with dueling, high-value acquisitions in the neuroscience space, and a pair of Phase II trial misses revealed by AbbVie on 11 November indicate that BMS may have gotten the better deal.

Key Takeaways
  • AbbVie’s emraclidine failed in a pair of Phase II studies of in schizophrenia, placing the value of last year’s $8.7bn Cerevel buyout in question.

AbbVie’s emraclidine, the main source of value in its $8.7bn Cerevel takeout, did not beat placebo in two Phase II...

More from Clinical Trials

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

More from Business

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.